

Abluminal biodegradable polymer biolimus-eluting stent  
everolimus-eluting stent (COMPARE II): a randomised,

Lancet, The

381, 651-660

DOI: [10.1016/s0140-6736\(12\)61852-2](https://doi.org/10.1016/s0140-6736(12)61852-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Targeting the Unstable Plaque in Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1099-1107.	1.1	20
2	Avoiding stent thrombosis: advances in technique, antiplatelet pharmacotherapy and stent design. <i>Interventional Cardiology</i> , 2013, 5, 179-201.	0.0	0
3	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	6.3	127
4	Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent. <i>Journal of the American College of Cardiology</i> , 2013, 62, 181-190.	1.2	194
5	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. <i>Lancet, The</i> , 2013, 381, 661-669.	6.3	173
6	Degradable polymer drug-eluting stents: a durable benefit?. <i>Lancet, The</i> , 2013, 381, 607-609.	6.3	0
7	SORT OUT V: a new episode in the DES wars. <i>Lancet, The</i> , 2013, 381, 609-611.	6.3	4
8	Key Advances in Clinical Cardiology. <i>Advances in Therapy</i> , 2013, 30, 369-386.	1.3	4
9	Biolimus-eluting stent with biodegradable polymer (Nobori®): an overview of recent clinical results, SORT OUT V and COMPARE II trials. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1293-1296.	0.6	4
10	Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy. <i>ISRN Cardiology</i> , 2013, 2013, 1-8.	1.6	18
11	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ, The</i> , 2013, 347, f6530-f6530.	3.0	194
12	Sorting out and comparing stents. <i>Nature Reviews Cardiology</i> , 2013, 10, 181-181.	6.1	0
13	Long-term Follow-up of Coronary Venous Bypass Graft Lesions Treated with a New Generation Drug-Eluting Stent with Bioabsorbable Polymer. <i>Journal of Interventional Cardiology</i> , 2013, 26, 425-433.	0.5	3
14	A Bumpy and Winding but Right Path to Domestic Drug-Eluting Coronary Stents. <i>Korean Circulation Journal</i> , 2013, 43, 645.	0.7	4
15	Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model. <i>Korean Circulation Journal</i> , 2013, 43, 744.	0.7	10
16	GW24-e3006â€¦Impact of the drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 18 randomised trials. <i>Heart</i> , 2013, 99, A163.1-A163.	1.2	0
17	Efficacy and Safety of Biodegradable Polymer Biolimus-Eluting Stents versus Durable Polymer Drug-Eluting Stents: A Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e78667.	1.1	10
18	Safety and Efficacy of Biodegradable Drug-Eluting vs. Bare Metal Stents: A Meta-Analysis from Randomized Trials. <i>PLoS ONE</i> , 2014, 9, e99648.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of biodegradable polymer biolimus A9-eluting stent versus durable polymer everolimus-eluting stent in diabetic patients: a prospective non-randomized single-centre long-term comparison. <i>Acta Cardiologica</i> , 2014, 69, 523-531.	0.3	3
20	Stent Thrombosis in Patients With Coronary Artery Disease Treated With Biodegradable Polymer Drug-Eluting Stents. <i>International Heart Journal</i> , 2014, 55, 213-218.	0.5	11
21	Advances in stent technologies and their effect on clinical efficacy and safety. <i>Medical Devices: Evidence and Research</i> , 2014, 7, 165.	0.4	13
22	Comparison of Biolimus A9-eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 322-329.	1.4	32
23	The Year in Cardiology 2013: coronary intervention. <i>European Heart Journal</i> , 2014, 35, 313-320.	1.0	12
24	The Nobori biolimus-eluting stent: update of available evidence. <i>Expert Review of Medical Devices</i> , 2014, 11, 275-282.	1.4	9
25	A Randomized Comparison of Novel Biodegradable Polymer- and Durable Polymer-coated Cobalt-Chromium Sirolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1352-1360.	1.1	39
26	Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: An update. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, E193-206.	0.7	31
27	Comparison of the Safety and Efficacy of Biodegradable Polymer Biolimus-eluting Stents and Durable Polymer Everolimus-eluting Stents: Propensity Score-Matched Analysis. <i>Journal of Interventional Cardiology</i> , 2014, 27, 399-407.	0.5	2
28	Impact of stent strut design in metallic stents and biodegradable scaffolds. <i>International Journal of Cardiology</i> , 2014, 177, 800-808.	0.8	136
29	Clinical Outcomes of Biodegradable Polymer Drug-eluting Stents for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials. <i>Clinical Cardiology</i> , 2014, 37, 440-453.	0.7	5
30	Incidence and Clinical Impact of Stent Fracture After the Nobori Biolimus-eluting Stent Implantation. <i>Journal of the American Heart Association</i> , 2014, 3, e000703.	1.6	27
31	Stent selection to minimize the risk of stent thrombosis. <i>Current Opinion in Cardiology</i> , 2014, 29, 578-585.	0.8	12
32	Biodegradable polymer Biolimus-eluting stent (Nobori&reg;) for the treatment of coronary artery lesions: review of concept and clinical results. <i>Medical Devices: Evidence and Research</i> , 2014, 7, 35.	0.4	9
33	The impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: A meta-analysis of 16 randomized trials. <i>Journal of Cardiology</i> , 2014, 64, 185-193.	0.8	15
34	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , 2014, 383, 2047-2056.	6.3	96
35	Safety and efficacy of degradable vs. permanent polymer drug-eluting stents: A meta-analysis of 18,395 patients from randomized trials. <i>International Journal of Cardiology</i> , 2014, 173, 100-109.	0.8	8
36	Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): Rationale and study design of the randomized TWENTE III multicenter trial. <i>American Heart Journal</i> , 2014, 167, 445-451.	1.2	29

#	ARTICLE	IF	CITATIONS
37	Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 889-895.	0.7	8
38	Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. <i>Lancet, The</i> , 2014, 383, 603-613.	6.3	740
39	Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 299-307.	1.2	269
40	Coronary stents: novel developments. <i>Heart</i> , 2014, 100, 1051-1061.	1.2	65
41	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 2111-2122.	6.3	224
42	ST elevation myocardial infarction: recent advances and updates. <i>Future Cardiology</i> , 2014, 10, 633-666.	0.5	1
43	One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: The Italian Nobori Stent Prospective Registry. <i>International Journal of Cardiology</i> , 2014, 177, 11-16.	0.8	8
44	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
45	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2014, 175, 484-491.	0.8	10
46	Drug-eluting stent technology: progress beyond the polymer. <i>European Heart Journal</i> , 2014, 35, 1991-1995.	1.0	10
47	A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 2014, 35, 2021-2031.	1.0	148
48	Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Drug-Eluting Stents for Patients With Coronary Artery Disease: An Update Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 379-385.	1.3	9
50	Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and bare-metal stents: Five-year follow-up optical coherence tomography study. <i>Atherosclerosis</i> , 2014, 237, 23-29.	0.4	18
51	NOBORI, a biodegradable-polymer biolimus-eluting stent versus durable-polymer drug-eluting stents: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 174, 151-153.	0.8	2
52	Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. <i>Lancet, The</i> , 2014, 383, 413-423.	6.3	171
53	Evidence from the Resorbable-polymer stent versus Unresorbable-polymer stent Deployment for coronary Intervention: (RUDI-2) registry. <i>International Journal of Cardiology</i> , 2014, 172, 472-475.	0.8	5
54	Clinical outcomes with 6 months dual antiplatelet therapy after implantation of Biolimus-A9 drug eluting coronary stents. <i>International Journal of Cardiology</i> , 2014, 172, 185-189.	0.8	5
55	Biodegradable Polymer DES Versus Durable Polymer Everolimus-eluting Stents for Patients Undergoing PCI: A Meta-analysis. <i>Heart Lung and Circulation</i> , 2014, 23, 496-502.	0.2	3

#	ARTICLE	IF	CITATIONS
56	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial. <i>American Heart Journal</i> , 2014, 168, 256-261.	1.2	16
57	Rosuvastatin increases myocardial microvessels in SHR rats. Role of thioredoxin-1 and peroxiredoxin-2 expression. <i>International Journal of Cardiology</i> , 2014, 174, 153-155.	0.8	4
59	Nobori Biolimus-Eluting Stent vs. Permanent Polymer Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 1858-1866.	0.7	12
60	Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. <i>Trials</i> , 2014, 15, 9.	0.7	14
61	Vascular response after implantation of biolimus A9-eluting stent with bioabsorbable polymer and everolimus-eluting stents with durable polymer. Results of the optical coherence tomography analysis of the BIOACTIVE randomized trial. <i>Revista Brasileira De Cardiologia Invasiva (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 572	0.1	0
63	Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the <scp>TWENTE</scp> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E76-82.	0.7	8
64	Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUction of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 409.	0.7	12
65	Coronary Artery Vessel Healing Pattern, Short and Long Term, After Implantation of the Everolimus-eluting Bioresorbable Vascular Scaffold. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	10
66	One-year follow-up of patients treated with new-generation polymer-based 38 mm everolimus-eluting stent: The P38 study. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 218-224.	0.7	11
67	Clinical utility of platinum chromium bare-metal stents in coronary heart disease. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 359.	0.4	14
68	Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial. <i>American Heart Journal</i> , 2015, 170, 210-215.	1.2	17
69	Long-Term Safety of Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2496-2507.	1.2	396
70	Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents. <i>Circulation</i> , 2015, 131, 74-81.	1.6	87
71	Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 17, jev203.	0.5	23
72	Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 461-464.	0.3	8
73	Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 183, 190-197.	0.8	4
75	Drug-Eluting Stents: the Past, Present, and Future. <i>Current Atherosclerosis Reports</i> , 2015, 17, 485.	2.0	39
76	Hemocompatibility Improvement of Chromium-Bearing Bare-Metal Stent Platform After Magneto-electropolishing. <i>Journal of Materials Engineering and Performance</i> , 2015, 24, 345-352.	1.2	1

#	ARTICLE	IF	CITATIONS
77	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1527-1535.	6.3	107
78	Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1545-1556.	0.8	3
79	Biodegradable Stent Platforms: Are We Heading in the Right Direction?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 957-959.	0.8	2
80	Event Rates in Randomized Clinical Trials Evaluating Cardiovascular Interventions and Devices. <i>American Journal of Cardiology</i> , 2015, 116, 355-363.	0.7	4
81	Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 491-497.	0.4	60
82	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 55 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	0.7	32
83	Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds. <i>Journal of the American College of Cardiology</i> , 2015, 65, 791-801.	1.2	189
84	Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. <i>European Journal of Medical Research</i> , 2015, 20, 21.	0.9	5
85	Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 1489-1496.	0.7	7
86	Clinical Impact of Intravascular Ultrasound-Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Biolimus-Eluting Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002592.	1.4	218
87	A comparison of drug eluting stent biocompatibility between third generation NOBORI biolimus A9-eluting stent and second generation XIENCE V everolimus-eluting stent in a porcine coronary artery model. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 351-357.	0.3	9
88	Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	55
89	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1089-1090.	1.2	3
90	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet, The</i> , 2015, 386, 655-664.	6.3	261
91	Controversies in Cardiology. , 2015, , .		0
92	Acute Thrombogenicity of a Durable Polymer Everolimus-Eluting Stent Relative to Contemporary Drug-Eluting Stents With Biodegradable Polymer Coatings Assessed Ex Vivo in a Swine Shunt Model. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1248-1260.	1.1	97
93	Neutrophil to Lymphocyte Ratio is Related to Stent Thrombosis and High Mortality in Patients With Acute Myocardial Infarction. <i>Angiology</i> , 2015, 66, 545-552.	0.8	52
94	Biodegradable polymer stents vs second generation drug eluting stents: A meta-analysis and systematic review of randomized controlled trials. <i>World Journal of Cardiology</i> , 2016, 8, 240.	0.5	16

#	ARTICLE	IF	CITATIONS
95	The Development of Coronary Artery Stents: From Bare-Metal to Bio-Resorbable Types. <i>Metals</i> , 2016, 6, 168.	1.0	32
96	Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature. <i>Journal of Cancer</i> , 2016, 7, 377-390.	1.2	46
97	Favorable outcomes in octogenarians treated with bioresorbable polymer drug-eluting stent. <i>Geriatrics and Gerontology International</i> , 2016, 16, 1246-1253.	0.7	0
98	Long-Term Clinical Outcomes of a Biodegradable Polymer-Based Biolimus-Eluting Stent. <i>Journal of Interventional Cardiology</i> , 2016, 29, 162-167.	0.5	2
101	Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. <i>American Heart Journal</i> , 2016, 178, 37-44.	1.2	20
102	A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 355-361.	0.3	21
103	Polymer Biodegradation Kinetics. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2259-2262.	1.2	2
104	Stent Polymers. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	60
105	Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq004 rgBT / Overlock 1	0.4	0
107	Angioscopic comparison of arterial repair after second-generation drug-eluting stent implantation into vulnerable and stable coronary plaques. <i>International Journal of Cardiology</i> , 2016, 221, 855-858.	0.8	7
108	Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (<sc>KAMIR</sc>). <i>Clinical Cardiology</i> , 2016, 39, 276-284.	0.7	4
109	The EBC TWO Study (European Bifurcation Coronary TWO). <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	102
110	Safety and efficacy profile of <i>bioresorbable</i>-polylactide-polymer-biolimus-eluting stents versus <i>durable</i>-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E173-E182.	0.7	5
111	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	104
112	Long-term outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents: A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 223, 1066-1071.	0.8	7
113	Effects of Intravascular Ultrasound-Guided Versus Angiography-Guided New-Generation Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2232-2239.	1.1	82
114	Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. <i>Lancet, The</i> , 2016, 388, 2607-2617.	6.3	208
115	Biodegradable polymer drug-eluting stents: non-inferiority waiting for superiority?. <i>Lancet, The</i> , 2016, 388, 2567-2568.	6.3	0

#	ARTICLE	IF	CITATIONS
116	6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1438-1446.	1.1	108
117	Complex coronary Bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial. <i>EuroIntervention</i> , 2016, 11, 1457-1467.	1.4	14
118	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 28-38.	1.1	31
119	From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI. <i>Expert Review of Medical Devices</i> , 2016, 13, 271-286.	1.4	29
120	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12
121	Drug-eluting stents to prevent stent thrombosis and restenosis. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 87-104.	0.6	34
122	Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT). <i>International Journal of Cardiology</i> , 2016, 202, 525-531.	0.8	17
123	A mixed treatment comparison for short- and long-term outcomes of bare-metal and drug-eluting coronary stents. <i>International Journal of Cardiology</i> , 2016, 202, 448-462.	0.8	4
124	Comparison of angioscopic findings among second-generation drug-eluting stents. <i>Journal of Cardiology</i> , 2017, 70, 297-302.	0.8	14
125	Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent. <i>Journal of Materials Science: Materials in Medicine</i> , 2017, 28, 54.	1.7	4
126	Bioresorbable Polymers and Stent Devices. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 12.	0.4	2
127	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial". <i>American Heart Journal</i> , 2017, 188, 11-17.	1.2	13
128	Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?. <i>Expert Review of Medical Devices</i> , 2017, 14, 325-334.	1.4	8
129	Outcomes of Acute Myocardial Infarction Patients Implanted With Biodegradable Polymer Biolimus-Eluting Stents Versus New-Generation Durable Polymer Drug-Eluting Stents: A Retrospective Analysis. <i>Angiology</i> , 2017, 68, 698-706.	0.8	0
130	Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 881-887.	0.7	35
131	Mid-term outcome of biolimus-eluting stents with biodegradable polymer. <i>Coronary Artery Disease</i> , 2017, 28, 457-464.	0.3	2
132	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. <i>Lancet, The</i> , 2017, 390, 1843-1852.	6.3	214
133	Polymer-free amphimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus. <i>International Journal of Cardiology</i> , 2017, 245, 69-76.	0.8	16



#	ARTICLE	IF	CITATIONS
134	What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?. JAMA Cardiology, 2017, 2, 1061.	3.0	7
135	Adverse cardiovascular events associated with biodegradable polymer drug-eluting stents and durable polymer everolimus-eluting stents. Medicine (United States), 2017, 96, e7510.	0.4	1
136	Left main coronary stenosis. Current Opinion in Cardiology, 2017, 32, 590-593.	0.8	2
137	Challenges in the Design and Interpretation of Noninferiority Trials. Journal of the American College of Cardiology, 2017, 70, 894-903.	1.2	28
138	Effect of biodegradable polymer drug-eluting stents versus biocompatible polymer everolimus-eluting stents: a meta-analysis. Acta Cardiologica, 2017, 72, 196-204.	0.3	2
139	7.28 Drug Eluting Stents . , 2017, , 548-590.		0
140	Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents. PLoS ONE, 2017, 12, e0183079.	1.1	4
141	Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents. Current Cardiology Reviews, 2017, 13, 139-154.	0.6	22
142	Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching. Yonsei Medical Journal, 2017, 58, 290.	0.9	3
143	Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 71, 832-841.	1.2	37
144	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	1.1	22
145	A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population. Cardiovascular Therapeutics, 2018, 36, e12319.	1.1	2
146	Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial. American Heart Journal, 2018, 198, 25-32.	1.2	8
147	Absorb bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in small vessel disease: A propensity matched analysis of COMPARE II, RAI, and MAASSTAD-ABSORB studies. Catheterization and Cardiovascular Interventions, 2018, 92, E115-E124.	0.7	6
148	Bioresorbable polymer drug-eluting stents. Lancet, The, 2018, 391, 935-936.	6.3	3
149	Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial. Catheterization and Cardiovascular Interventions, 2018, 91, 410-416.	0.7	9
150	Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis. Catheterization and Cardiovascular Interventions, 2018, 92, 285-299.	0.7	9
152	From bare metal to barely anything: an update on coronary stenting. Heart, 2018, 104, 533-540.	1.2	11

#	ARTICLE	IF	CITATIONS
153	Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patients with acute myocardial infarction. <i>Postępy W Kardiologii Interwencyjnej</i> , 2018, 14, 347-355.	0.1	4
154	A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells. <i>Scientific Reports</i> , 2018, 8, 16551.	1.6	18
155	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3287-3297.	1.2	73
156	Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1235-1245.	6.3	112
157	Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007331.	1.4	23
158	Effectiveness and Safety of Biolimus A9â„-Eluting stEnt in Patients with AcUTE Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study). <i>Yonsei Medical Journal</i> , 2018, 59, 72.	0.9	2
159	Cardiovascular and Noncardiovascular Death After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006488.	1.4	21
160	Development of drug-eluting stents (DES). , 2018, , 45-56.		1
161	A meta-analysis of randomized controlled trials to compare long-term clinical outcomes of bioabsorbable polymer and durable polymer drug-eluting stents. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 105-113.	1.8	15
162	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	1.0	4,537
163	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	0.6	402
164	Clinical outcomes and complications of treatment with supraflex stent in patients with coronary artery disease: One-year follow-up. <i>European Journal of Translational Myology</i> , 2019, 29, 8231.	0.8	5
165	Major ischaemic and bleeding risks following current drug-eluting stent implantation: Are there differences across current drug-eluting stent types in real life?. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 469-484.	0.7	5
166	<p>Real-World Use Of Ultrathin-Strut Biodegradable Polymerâ€Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 439-447.	1.0	4
167	The Smokerâ€™s Paradox Revisited. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1941-1950.	1.1	20
168	Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. <i>International Journal of Cardiology</i> , 2019, 283, 67-72.	0.8	19
169	Biodegradable Polymers and Stents: the Next Generation?. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	6
170	Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantationâ€Individual patient data pooled analysis from 6 randomized controlled trials. <i>American Heart Journal</i> , 2019, 213, 105-111.	1.2	27

#	ARTICLE	IF	CITATIONS
171	Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomized SORT OUT IX trial. <i>American Heart Journal</i> , 2019, 213, 1-7.	1.2	10
172	Abulminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes mellitus. <i>International Journal of Cardiology</i> , 2019, 290, 40-44.	0.8	8
173	Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR). <i>European Heart Journal</i> , 2019, 40, 2607-2615.	1.0	17
175	One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI. <i>Atherosclerosis</i> , 2019, 284, 102-109.	0.4	15
176	Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 624-633.	1.1	27
177	Use of Mortality as an Endpoint in Noninferiority Trials May Lead to Ethically Problematic Conclusions. <i>Journal of General Internal Medicine</i> , 2019, 34, 618-623.	1.3	7
178	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2572-2584.	1.2	31
179	Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice. <i>Coronary Artery Disease</i> , 2019, 30, 255-262.	0.3	7
180	Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR. <i>Heart and Vessels</i> , 2019, 34, 237-250.	0.5	5
181	Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 342-347.	0.7	8
182	The EluNIR <sup>TM</sup> Ridaforolimus Eluting Coronary Stent System. <i>Expert Review of Medical Devices</i> , 2019, 16, 71-76.	1.4	7
183	Safety and Efficacy of Biodegradable Polymer-biolimus-eluting Stents (BP-BES) Compared with Durable Polymer-everolimus-eluting Stents (DP-EES) in Patients Undergoing Complex Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2019, 49, 69.	0.7	7
184	Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent. <i>Circulation</i> , 2019, 139, 67-77.	1.6	33
185	Five-Year Results of the Bioflow-III Registry: Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 63-69.	0.3	12
187	Impact of stent generation on 2-year clinical outcomes in ST-segment elevation myocardial infarction patients with multivessel disease who underwent culprit-only or multivessel percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, E40-E55.	0.7	16
188	The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective. <i>Netherlands Heart Journal</i> , 2020, 28, 78-87.	0.3	4
189	Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. <i>BMJ, The</i> , 2020, 370, m2836.	3.0	165
190	Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 141, 2052-2063.	1.6	48

#	ARTICLE	IF	CITATIONS
191	Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-9.	0.5	7
192	Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival. <i>JAMA Oncology</i> , 2020, 6, e200249.	3.4	83
193	Three-year follow up of biodegradable polymer cobalt-chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: Pooled analysis of CREDIT II and CREDIT III trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 565-571.	0.7	2
194	Safety and Performance of the Orsiro Sirolimus-Eluting Stent in the Treatment of All-Comers Patient Population in Daily Clinical Practice. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1348-1354.	0.3	6
195	Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome. <i>Circulation</i> , 2021, 143, 1081-1091.	1.6	33
196	Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e018366.	1.6	8
197	Second generation drug-eluting stents: a focus on safety and efficacy of current devices. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 107-127.	0.6	4
198	Parametric Optimization of 3D Printed Hydrogel-Based Cardiovascular Stent. <i>Pharmaceutical Research</i> , 2021, 38, 885-900.	1.7	11
199	Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. <i>EuroIntervention</i> , 2021, 17, 233-239.	1.4	4
200	A randomised comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: a pre-specified analysis of the SMART-DATE trial. <i>EuroIntervention</i> , 2021, 17, e411-e417.	1.4	2
201	The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy. <i>Polymers</i> , 2021, 13, 446.	2.0	9
202	Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1215-1221.	1.1	85
203	Comparison of Contemporary Drug-eluting Coronary Stents – Is Any Stent Better than the Others?. <i>Heart International</i> , 2020, 14, 34.	0.4	3
204	Ideal coronary stent: development, characteristics, and vessel size impact. <i>Annales Academiae Medicae Silesiensis</i> , 2020, 74, 191-197.	0.1	1
205	The Synergy stent in high-bleeding risk patients: why design matters. <i>Minerva Cardioangiologica</i> , 2018, 66, 646-658.	1.2	3
206	An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial). <i>Health Technology Assessment</i> , 2016, 20, 1-188.	1.3	51
207	A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, e20-e24.	0.6	6
208	Preclinical evaluation of a novel abluminal surface coated sirolimus eluting stent with biodegradable polymer matrix. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 254-63.	0.7	10

#	ARTICLE	IF	CITATIONS
209	Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 414-9.	0.7	6
210	Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2013, 07, 65.	0.1	14
211	Reduction in the Corrosion Rate of Magnesium and Magnesium Alloy Specimens and Implications for Plain Fully Bioresorbable Coronary Artery Stents: A Review. <i>World Journal of Engineering and Technology</i> , 2016, 04, 597-597.	0.3	4
212	Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. <i>EuroIntervention</i> , 2017, 13, 1336-1344.	1.4	11
213	Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. <i>EuroIntervention</i> , 2018, 13, 1904-1913.	1.4	18
214	Two-year outcome after biodegradable polymer sirolimus- and biolimus-eluting coronary stents (from) Tj ETQq1 1 0.784314 rgBT /Overl	1.4	17
215	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. <i>EuroIntervention</i> , 2018, 14, 692-699.	1.4	11
216	A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. <i>EuroIntervention</i> , 2018, 14, 86-93.	1.4	11
217	Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: the MASTER study. <i>EuroIntervention</i> , 2019, 14, e1836-e1842.	1.4	14
218	Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. <i>EuroIntervention</i> , 2018, 14, e343-e351.	1.4	21
219	Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. <i>EuroIntervention</i> , 2014, 10, 717-723.	1.4	27
220	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer) Tj ETQq1 1 0.784314 rgBT /Overl	1.4	32
221	The EXCEL and NOBLE trials: similarities, contrasts and future perspectives for left main revascularisation. <i>EuroIntervention</i> , 2015, 11, V115-V119.	1.4	16
222	Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. <i>EuroIntervention</i> , 2016, 12, e557-e565.	1.4	11
223	Periprocedural myocardial infarction in stent trials: how universal is the third universal definition?. <i>EuroIntervention</i> , 2016, 12, 813-817.	1.4	4
224	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. <i>EuroIntervention</i> , 2013, 9, 75-83.	1.4	60
225	Polymer coatings on drug-eluting stents: Samsonâ€™s hair and Achillesâ€™ heel?. <i>EuroIntervention</i> , 2013, 9, 302-305.	1.4	19
226	Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. <i>EuroIntervention</i> , 2013, 9, 308-315.	1.4	38

#	ARTICLE	IF	CITATIONS
227	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	1.4	251
228	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention, 2016, 11, 1372-137.	1.4	60
229	STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 EuroIntervention, 2016, 11, e1619-e1626.	1.4	19
230	Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry. EuroIntervention, 2016, 11, 1106-1110.	1.4	35
231	2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2019, 14, 1435-1534.	1.4	367
233	Outcomes of biodegradable polymer sirolimus-eluting PROLIM stent in patients with coronary artery disease. Results of 12-month follow-up of prospective registry. Kardiologia Polska, 2016, 74, 411-417.	0.3	1
234	ComparaÃ§Ã£o de Stents FarmacolÃ³gicos com PolÃªmero DurÃ¡vel ou BiorreabsorvÃ¡vel: Resultados do Ultrassom IntracoronÃ¡rio do Estudo BIOACTIVE. Revista Brasileira De Cardiologia Invasiva, 2014, 22, 245-251.	0.1	1
236	Drug-Eluting Stents and Coronary Artery Disease. , 2015, , 495-524.		0
237	Clinical Outcome Comparison of Everolimus- and Biolimus-eluting Stents in Patients with Acute Myocardial Infarction. Korean Journal of Medicine, 2015, 89, 418-427.	0.1	0
238	Devices: Safety Assurance. , 0, , 2620-2628.		0
239	Can Platforms Affect the Safety and Efficacy of Drug-Eluting Stents in the Era of Biodegradable Polymers?: A Meta-Analysis of 34,850 Randomized Individuals. PLoS ONE, 2016, 11, e0151259.	1.1	0
240	Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. Texas Heart Institute Journal, 2016, 43, 126-130.	0.1	5
241	The principles and practice of audit in coronary intervention. , 2017, , 639-646.		0
242	Stent Technology. , 2018, , 137-159.		0
243	Safety and Efficacy of Ultra-Thin, Biodegradable Polymer Coated Sirolimus-Eluting Supralimus-Core Stents in Real-World Patients: Outcomes at 24-Month Follow-Up. World Journal of Cardiovascular Diseases, 2018, 08, 523-532.	0.0	0
244	Plaque Erosion. , 2020, , 79-89.		0
245	Emerging therapies in coronary balloon angioplasty, stenting, and bioabsorbable scaffolds. , 2020, , 527-557.		0
246	Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial. Journal of Clinical Medicine, 2021, 10, 5103.	1.0	0

#	ARTICLE	IF	CITATIONS
247	Ultra-thin (60 Åµm), Ultra-long (â‰¥40 mm) Sirolimus Eluting Stent - Study of clinical and safety profile among real-world patients. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 111-119.	0.5	1
248	Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: an experience in real-world Indian patients. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 364-369.	0.5	2
249	Serial Angioscopic Evaluation of Arterial Repair After the Implantation of Drug-Coated Stent at the Culprit of Acute Coronary Syndrome. <i>Journal of Coronary Artery Disease</i> , 2020, 26, 9-11.	0.1	0
250	Clinical safety and efficacy of World's thinnest (50 Î¼m), very long (>40 mm) Everolimus Eluting Stent (SES) among real world patients. <i>American Journal of Cardiovascular Disease</i> , 2020, 10, 317-328.	0.5	0
251	DEVELOPMENT OF SIROLIMUS COATED ELUTING STENT USING ABLUMINAL COATING TECHNOLOGY. <i>Indian Drugs</i> , 2018, 55, 56-62.	0.1	0
252	Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. , 2022, 1, 100004.		2
253	Current status and future direction of metallic and polymeric materials for advanced vascular stents. <i>Progress in Materials Science</i> , 2022, 126, 100922.	16.0	19
254	A Comparative Analysis of Two Biolimus-Eluting Biodegradable Stents: Evaluation of the Equivalence of 6 Months Versus 12 Months of DAPT Following Biolimus-Eluting Stent Implantation in Acute Coronary Syndrome (EQUUS). , 2022, 1, 61.		0
255	Drug-eluting stents for the treatment of coronary artery disease: A review of recent advances. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 269-280.	2.4	12
256	Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials. <i>EuroIntervention</i> , 2022, 17, 1318-1329.	1.4	10
257	Real-World Long-Term Clinical Outcomes of Ultrathin Strut Biodegradable Polymer Drug-Eluting Stents in Korean ST-Segment-Elevation Myocardial Infarction (STEMI) Patients with or without Acute Heart Failure Undergoing Primary Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2021, 10, 5898.	1.0	2
258	Long-Term Clinical Outcomes Between Biodegradable and Durable Polymer Drug-Eluting Stents: A Nationwide Cohort Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 873114.	1.1	2
261	Safety and efficacy of 48â€‰mm Xience Xpedition everolimusâ€‰eluting stent for the treatment of long coronary lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 100, 179-187.	0.7	4
262	Comparison of biodegradable and durable polymer drug-eluting stents in acute coronary syndrome: a meta-analysis. <i>BMJ Open</i> , 2022, 12, e058075.	0.8	5
263	Long-term clinical outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer sirolimus-eluting stents. <i>AsiaIntervention</i> , 2018, 4, 77-86.	0.1	1
264	Three-Year Clinical Outcomes of a Thin-Strut Biodegradable-Polymer Everolimus-Eluting Stent in Patients With Acute Coronary Syndrome. , 0, 2, .		0
265	A Randomized Controlled Trial of a Biodegradable Polymer, Microcrystalline Sirolimus-Eluting Stent (MiStent) versus Another Biodegradable Polymer Sirolimus-Eluting Stent (TIVOLI): The DESSOLVE-C Trial. , 2023, 3, 1-8.		0
266	Utility of the ACC/AHA Lesion Classification to Predict Outcomes After Contemporary DES Treatment: Individual Patient Data Pooled Analysis From 7 Randomized Trials. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2

#	ARTICLE	IF	CITATIONS
267	Complementary evidence on the performance of coronary stents generated by a randomized controlled trial and a worldwide registry. American Heart Journal, 2023, 261, 35-44.	1.2	0